Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Ping-Cheng Yi"'
Autor:
Martin Widschwendter, Matthew Burnell, Lindsay Fraser, Adam N. Rosenthal, Sue Philpott, Daniel Reisel, Louis Dubeau, Mark Cline, Yang Pan, Ping-Cheng Yi, D. Gareth Evans, Ian J. Jacobs, Usha Menon, Charles E. Wood, William C. Dougall
Publikováno v:
EBioMedicine, Vol 2, Iss 10, Pp 1331-1339 (2015)
Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the conse
Externí odkaz:
https://doaj.org/article/c1a750bb46dc475e933cb1495b528c24
Autor:
Michael Lee, Rick Sorensen, Marianna Zavodovskaya, Ping Cheng Yi, Audrey Goddard, Matthew Peach
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/8922f2ed7b9945f1849e78391de5fa0d
Autor:
Michael Gordon, Anthony Tolcher, James Strauss, Rick Sorensen, Marianna Zavodovskaya, Ping Cheng Yi, Audrey Goddard, Matthew Peach, Kathleen Mahoney, Xiaoyun Yang, Kai-Wen Lin, Biao Li, Anna Seto, Tianling Chen, Juliane Jürgensmeier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/347886e0b29943a29b63e012d170d625
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 3. Mean (SD) TIRA plasma concentration. Cycle 1 Day 8 data are shown in patients receiving TIRA monotherapy with A) TIRA/IDELA, and B) TIRA/ENTO*
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11dcc13096ac288a3c0fe922698b5f6f
https://doi.org/10.1158/1078-0432.22476726.v1
https://doi.org/10.1158/1078-0432.22476726.v1
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Table 1 summarizes study inclusion and exclusion criteria. Supplemental Table 2 shows the doses and dose-escalation strategy used in this study. Supplemental Table 3 defines the dose-limiting toxicities that guided dose escalation. Suppl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2661752db628906be946811e30742a6f
https://doi.org/10.1158/1078-0432.22476717
https://doi.org/10.1158/1078-0432.22476717
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 4. Free BTK levels at baseline and trough TIRA concentration for CLL patients treated with 80 mg TIRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14a30975b8192d0017300139da2604cd
https://doi.org/10.1158/1078-0432.22476720.v1
https://doi.org/10.1158/1078-0432.22476720.v1
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Supplemental Figure 2. Patient disposition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de2f892b658eb79b3f7169372bcb174e
https://doi.org/10.1158/1078-0432.22476729
https://doi.org/10.1158/1078-0432.22476729
Autor:
Christopher D. Fegan, Juliane M. Jürgensmeier, Pankaj Bhargava, Ziqian Zhou, Xi Huang, Rita Humeniuk, Ping Cheng Yi, Siddhartha S. Mitra, Martin J.S. Dyer, Lionel Karlin, Ebenezer A. Kio, Simon A. Rule, Peter Hillmen, Harriet S. Walter, Charles Herbaux, Alexey V. Danilov
Purpose:Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape pathways and deepen responses. This open-label, phase Ib, sequential dose-e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf6dda7779f6dd51726c8df152e2017a
https://doi.org/10.1158/1078-0432.c.6529473
https://doi.org/10.1158/1078-0432.c.6529473
Autor:
Kathleen M. Mahoney, Audrey Goddard, Matthew Peach, Marianna Zavodovskaya, Michael S. Gordon, Rick Sorensen, James Strauss, Kai-Wen Lin, Xiaoyun Yang, Tianling Chen, Juliane Jürgensmeier, Anna Seto, Anthony W. Tolcher, Ping Cheng Yi, Biao Li
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundGS-1423 is a first-in-class bifunctional molecule comprised of an anti-CD73 antibody fused to the extracellular domain of TGFβ receptor II (TGFβRII). GS-1423 is designed to inhibit CD73-mediated adenosine production and neutralize active
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d6eb96c80a8acdc2c2cf68dd8863129
https://doaj.org/article/347886e0b29943a29b63e012d170d625
https://doaj.org/article/347886e0b29943a29b63e012d170d625
Autor:
Audrey Goddard, Michael Lee, Matthew Peach, Rick Sorensen, Ping Cheng Yi, Marianna Zavodovskaya
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundInhibiting ecto-5’-nucleotidase (CD73) to reduce immunosuppressive adenosine in the tumor microenvironments is an anti-tumor strategy currently explored in clinical trials. Measuring soluble CD73 (sCD73) activity in plasma to evaluate pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4d01b455cecb624ce61aab39b00472c
https://doi.org/10.1136/jitc-2021-sitc2021.032
https://doi.org/10.1136/jitc-2021-sitc2021.032